Palvella Therapeutics’ (PVLA) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Palvella Therapeutics (NASDAQ:PVLA) in a report issued on Tuesday,Benzinga reports. The firm currently has a $38.00 price target on the stock.

A number of other research firms have also issued reports on PVLA. Cantor Fitzgerald assumed coverage on Palvella Therapeutics in a research note on Wednesday, December 18th. They set an “overweight” rating on the stock. TD Cowen started coverage on Palvella Therapeutics in a research report on Wednesday, February 5th. They set a “buy” rating and a $44.00 price target on the stock.

Palvella Therapeutics Stock Up 2.7 %

Palvella Therapeutics stock opened at $16.15 on Tuesday. The company has a market capitalization of $181.20 million, a P/E ratio of -1.33 and a beta of 0.68. Palvella Therapeutics has a 1-year low of $6.20 and a 1-year high of $22.32.

Insider Transactions at Palvella Therapeutics

In other Palvella Therapeutics news, Director George M. Jenkins acquired 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, December 18th. The stock was bought at an average price of $12.93 per share, with a total value of $51,720.00. Following the completion of the purchase, the director now owns 180,671 shares of the company’s stock, valued at approximately $2,336,076.03. This represents a 2.26 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 6.39% of the company’s stock.

Institutional Trading of Palvella Therapeutics

An institutional investor recently bought a new position in Palvella Therapeutics stock. BML Capital Management LLC bought a new stake in Palvella Therapeutics (NASDAQ:PVLA) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 42,130 shares of the company’s stock, valued at approximately $506,000. Palvella Therapeutics makes up about 0.3% of BML Capital Management LLC’s investment portfolio, making the stock its 18th biggest position. BML Capital Management LLC owned about 0.38% of Palvella Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 40.11% of the company’s stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.